Early versus late treatment of spinal cord compression with long-term intrathecal enzyme replacement therapy in canine mucopolysaccharidosis type I.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Molecular Genetics and Metabolism

• Publication date

  2010-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ymgme.2010.06.020PMID 20655780PMCID PMC2950221
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Repeated intrathecal injections of recombinant human 4-sulphatase remove dural storage in mature mucopolysaccharidosis VI cats primed with a short-course tolerisation regimen.

  2010cited by this paper
• Combination of enzyme replacement and hematopoietic stem cell transplantation as therapy for Hurler syndrome

  2008cited by this paper
• Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I.

  2008cited by this paper
• Tandem mass spectrometry for the direct assay of lysosomal enzymes in dried blood spots: application to screening newborns for mucopolysaccharidosis IVA.

  2008cited by this paper
• Tandem mass spectrometry for the direct assay of lysosomal enzymes in dried blood spots: application to screening newborns for mucopolysaccharidosis I.

  2008cited by this paper
• Tandem mass spectrometry for the direct assay of lysosomal enzymes in dried blood spots

  2008cited by this paper
• Radiographic evaluation of bones and joints in mucopolysaccharidosis I and VII dogs after neonatal gene therapy.

  2008cited by this paper
• Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid.

  2007influential reference
• Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failure

  2007cited by this paper
• A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years.

  2007cited by this paper
• The MPS I registry: design, methodology, and early findings of a global disease registry for monitoring patients with Mucopolysaccharidosis Type I.

  2007cited by this paper
• Long-term Outcomes of Adaptive Functions for Children with Mucopolysaccharidosis I (Hurler Syndrome) Treated with Hematopoietic Stem Cell Transplantation

  2006cited by this paper
• Multilevel myelopathy in Maroteaux-Lamy syndrome and review of the literature.

  2005cited by this paper
• Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I.

  2004cited by this paper
• Successful induction of immune tolerance to enzyme replacement therapy in canine mucopolysaccharidosis I.

  2004cited by this paper
• Laminectomy and Posterior Cervical Plating for Multilevel Cervical Spondylotic Myelopathy and Ossification of the Posterior Longitudinal Ligament: Effects on Cervical Alignment, Spinal Cord Compression, and Neurological Outcome

  2003cited by this paper
• Laminectomy and posterior cervical plating for multilevel cervical spondylotic myelopathy and ossification of the posterior longitudinal ligament: effects on cervical alignment, spinal cord compression, and neurological outcome.

  2003cited by this paper
• The Metabolic and Molecular Bases of Inherited Disease

  2001cited by this paper
• Enzyme-replacement therapy in mucopolysaccharidosis I.

  2001cited by this paper
• Mucopolysaccharidoses and spinal cord compression: case report and review of the literature with implications of bone marrow transplantation.

  2000cited by this paper
• Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I.

  1996cited by this paper
• Handbook of Veterinary Neurology

  1993cited by this paper
• Architecture of the canine IDUA gene and mutation underlying canine mucopolysaccharidosis I.

  1992cited by this paper
• Cervical myelopathy due to dural compression in mucopolysaccharidosis.

  1982cited by this paper
• Myelography Features of Mucopolysaccharidoses: A New Sign1

  1977cited by this paper
• Myelographic features of mucopolysaccharidoses: a new sign.

  1977cited by this paper
• Cervical Cord Compression in Mucopolysaccharidosis

  1973cited by this paper

• Intravenous gene therapy improves lifespan and clinical outcomes in feline Sandhoff Disease

  2024cites this paper
• Newborn Screening for Mucopolysaccharidosis Type I: Past, Present and Future

  2023cites this paper
• Intrathecal Delivery and its Applications in Leptomeningeal Disease.

  2022cites this paper
• Enzyme replacement combinational therapy: effective treatments for mucopolysaccharidoses

  2021cites this paper
• MPS I: Early diagnosis, bone disease and treatment, where are we now?

  2021cites this paper
• Abnormal epiphyseal development in a feline model of Sandhoff disease

  2020cites this paper
• Canine Models of Inherited Musculoskeletal and Neurodegenerative Diseases

  2020cites this paper
• A deletion of IDUA exon 10 in a family of Golden Retriever dogs with an attenuated form of mucopolysaccharidosis type I

  2020cites this paper
• Improving diagnosis and treatment outcomes in mucopolysaccharidoses

  2019cites this paper
• Targeted enzyme delivery systems in lysosomal disorders: an innovative form of therapy for mucopolysaccharidosis

  2019cites this paper
• Large animal models contribute to the development of therapies for central and peripheral nervous system dysfunction in patients with lysosomal storage diseases.

  2019cites this paper
• New treatments for the mucopolysaccharidoses: from pathophysiology to therapy

  2018cites this paper
• Neurological manifestations of lysosomal disorders and emerging therapies targeting the CNS.

  2018cites this paper
• Current Approaches to the Treatment of Hunter Syndrome

  2018cites this paper
• Characterization of a Mucopolysaccharidosis Type I and GalNAc Transferase deficiency double knockout mouse

  2018cites this paper
• Intrathecal/Intracerebroventricular enzyme replacement therapy for the mucopolysaccharidoses: efficacy, safety, and prospects

  2018cites this paper
• Chronic Enzyme Replacement to the Brain of a Late Infantile Neuronal Ceroid Lipofuscinosis Mouse Has Differential Effects on Phenotypes of Disease

  2017cites this paper
• Canine and Feline Models of Human Genetic Diseases and Their Contributions to Advancing Clinical Therapies


  2017cites this paper
• Low-dose, continual enzyme delivery ameliorates some aspects of established brain disease in a mouse model of a childhood-onset neurodegenerative disorder.

  2016cites this paper
• Nonsense Suppression as an Approach to Treat Lysosomal Storage Diseases

  2016cites this paper
• Neonatal tolerance induction enables accurate evaluation of gene therapy for MPS I in a canine model.

  2016cites this paper
• Pentosan Polysulfate: Oral Versus Subcutaneous Injection in Mucopolysaccharidosis Type I Dogs

  2016influential citation
• Pathogenesis and treatment of spine disease in the mucopolysaccharidoses.

  2016cites this paper
• Intrathecal adeno-associated virus vector delivery for mucopolysaccharidosis type I

  2015cites this paper
• A Review of Gene Therapy in Canine and Feline Models of Lysosomal Storage Disorders

  2015cites this paper
• Mucopolysaccharidosis-like phenotype in feline Sandhoff disease and partial correction after AAV gene therapy.

  2015cites this paper
• Safety of laronidase delivered into the spinal canal for treatment of cervical stenosis in mucopolysaccharidosis I.

  2015cites this paper
• Delivery of therapeutic protein for prevention of neurodegenerative changes: comparison of different CSF-delivery methods.

  2015cites this paper
• UvA-DARE ( Digital Academic Repository ) Improving the diagnosis and treatment of MPS

  2015cites this paper
• Diagnosis, classification and treatment of mucopolysaccharidosis type I

  2015cites this paper
• Improving the diagnosis and treatment of MPS I

  2015cites this paper
• Long-term nonsense suppression therapy moderates MPS I-H disease progression.

  2014cites this paper
• Intrathecal gene therapy corrects CNS pathology in a feline model of mucopolysaccharidosis I.

  2014cites this paper
• Effects of Neonatal Enzyme Replacement Therapy and Simvastatin Treatment on Cervical Spine Disease in Mucopolysaccharidosis I Dogs

  2014cites this paper
• Widespread correction of central nervous system disease after intracranial gene therapy in a feline model of Sandhoff disease

  2014cites this paper
• Disease stage determines the efficacy of treatment of a paediatric neurodegenerative disease

  2014cites this paper
• Approaches and Considerations Towards a Safe and EffectiveAdeno-Associated Virus Mediated Therapeutic Intervention for GM1-Gangliosidosis: A Dissertation

  2014cites this paper
• Isokinetic muscle strength differences in patients with mucopolysaccharidosis I, II, and VI

  2014cites this paper
• Intra-articular enzyme replacement therapy with rhIDUA is safe, well-tolerated, and reduces articular GAG storage in the canine model of mucopolysaccharidosis type I.

  2014cites this paper
• Features of brain MRI in dogs with treated and untreated mucopolysaccharidosis type I.

  2013cites this paper
• Postnatal progression of bone disease in the cervical spines of mucopolysaccharidosis I dogs.

  2013cites this paper
• Mucopolysaccharide Disorders in Orthopaedic Surgery

  2013cites this paper
• Quantification of Glycosaminoglycans in Urine by Isotope‐Dilution Liquid Chromatography‐Electrospray Ionization Tandem Mass Spectrometry

  2013cites this paper
• Endocrine Disorders Emerging treatment options for the mucopolysaccharidoses

  2012cites this paper
• Spinal Cord Compression in Maroteaux-Lamy Syndrome: Case Report and Review of the Literature with Effects of Enzyme Replacement Therapy

  2012cites this paper
• Systemic Administration of Tripeptidyl Peptidase I in a Mouse Model of Late Infantile Neuronal Ceroid Lipofuscinosis: Effect of Glycan Modification

  2012cites this paper
• Emerging treatment options for the mucopolysaccharidoses

  2012cites this paper
• Diagnosis and treatment trends in mucopolysaccharidosis I: findings from the MPS I Registry

  2012cites this paper
• Emerging treatment options for the mucopolysaccharidoses

  2012cites this paper
• Treatment of canine fucosidosis by intracisternal enzyme infusion.

  2011cites this paper
• Intracisternal enzyme replacement therapy in lysosomal storage diseases: routes of absorption into brain

  2011cites this paper
• Biodistribution and pharmacodynamics of recombinant human alpha-L-iduronidase (rhIDU) in mucopolysaccharidosis type I-affected cats following multiple intrathecal administrations.

  2011cites this paper
• Orthopaedic aspects of mucopolysaccharidoses.

  2011cites this paper
• Enzyme replacement reduces neuropathology in MPS IIIA dogs.

  2011cites this paper
• Ocular lesions in canine mucopolysaccharidosis I and response to enzyme replacement therapy.

  2011cites this paper
• Analysis of glycosaminoglycans in cerebrospinal fluid from patients with mucopolysaccharidoses by isotope-dilution ultra-performance liquid chromatography-tandem mass spectrometry.

  2011cites this paper
• Glycosaminoglycan storage in neuroanatomical regions of mucopolysaccharidosis I dogs following intrathecal recombinant human iduronidase

  2011cites this paper
• Arterial Pathology in Canine Mucopolysaccharidosis-I and Response to Therapy

  2010cites this paper